{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:36:29Z","timestamp":1778949389054,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,2]],"date-time":"2019-02-02T00:00:00Z","timestamp":1549065600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.nefro.2018.10.016","type":"journal-article","created":{"date-parts":[[2019,3,29]],"date-time":"2019-03-29T02:33:36Z","timestamp":1553826816000},"page":"473-481","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Onco-Nefrolog\u00eda: c\u00e1ncer, quimioterapia y ri\u00f1\u00f3n"],"prefix":"10.1016","volume":"39","author":[{"given":"Angel L.M.","family":"de Francisco","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Mac\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Fernando","family":"Quintana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borja","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isidro","family":"Torregrosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefro.2018.10.016_bib0210","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s12094-016-1607-9","article-title":"Cancer incidence in Spain, 2015","volume":"19","author":"Galceran","year":"2017","journal-title":"Clin Transl Oncol."},{"key":"10.1016\/j.nefro.2018.10.016_bib0215","first-page":"78","article-title":"Prevalence of chronic renal disease in Spain: Results of the EPIRCE study","volume":"30","author":"Otero","year":"2010","journal-title":"Nefrologia."},{"key":"10.1016\/j.nefro.2018.10.016_bib0220","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1523-1755.1999.00548.x","article-title":"Paraneoplastic glomerulopathies: New insights into an old entity","volume":"56","author":"Ronco","year":"1999","journal-title":"Kidney Int."},{"key":"10.1016\/j.nefro.2018.10.016_bib0225","unstructured":"Glezerman I, Jaimes EA: Chemotherapy and kidney injury. American Society of Nephrology Onco-Nephrology Curriculum. Disponible en: https:\/\/www.asn-online.org\/education\/distancelearning\/curricula\/onco\/Chapter11.pdf."},{"key":"10.1016\/j.nefro.2018.10.016_bib0230","unstructured":"Edeani A, Cohen EP. Radiation nephropathy. American Society of Nephrology Onco-Nephrology Curriculum. Disponible en: https:\/\/www.asnonline.org\/education\/distancelearning\/curricula\/onco\/Chapter10.pdf"},{"key":"10.1016\/j.nefro.2018.10.016_bib0235","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(06)70803-8","article-title":"Chronic kidney disease after nephrectomy in patients with renal cortical tumours: A retrospective cohort study","volume":"7","author":"Huang","year":"2006","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.nefro.2018.10.016_bib0240","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0140-6736(99)06154-1","article-title":"Cancer in patients on dialysis for end-stage renal disease: An international collaborative study","volume":"354","author":"Maisonneuve","year":"1999","journal-title":"Lancet."},{"key":"10.1016\/j.nefro.2018.10.016_bib0245","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1600-6143.2004.00450.x","article-title":"Cancer after kidney transplantation in the United States","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant."},{"key":"10.1016\/j.nefro.2018.10.016_bib0250","unstructured":"Monga D, Jhaveri KD. Glomerular diseases and c\u00e1ncer. American Society of Nephrology Onco-Nephrology Curriculum. Disponible en: https:\/\/www.asn-online.org\/education\/distancelearning\/curricula\/onco\/Chapter6.pdf"},{"key":"10.1016\/j.nefro.2018.10.016_bib0255","article-title":"Da\u00f1o renal agudo asociado a la administraci\u00f3n intravascular de contraste yodado en el paciente de riesgo y oncol\u00f3gico. Una posici\u00f3n de expertos","author":"De Francisco","year":"2018","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.nefro.2018.10.016_bib0260","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jvs.2013.12.039","article-title":"Impact of cumulative intravascular contrast exposure on renal function in patients with occlusive and aneurysmal vascular disease","volume":"59","author":"Kougias","year":"2014","journal-title":"J Vasc Surg."},{"key":"10.1016\/j.nefro.2018.10.016_bib0265","first-page":"1011","article-title":"Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography","volume":"24","author":"Hong","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.nefro.2018.10.016_bib0270","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for acute kidney injury","volume":"2","year":"2012","journal-title":"Kidney Inter Suppl"},{"key":"10.1016\/j.nefro.2018.10.016_bib0275","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000363721","article-title":"Renal functional reserve and renal recovery after acute kidney injury","volume":"127","author":"Sharma","year":"2014","journal-title":"Nephron Clin Pract."},{"key":"10.1016\/j.nefro.2018.10.016_bib0280","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/sj.bjc.6605979","article-title":"Cancer and renal insufficiency results of the BIRMA study","volume":"7","author":"Janus","year":"2010","journal-title":"Br J Cancer."},{"key":"10.1016\/j.nefro.2018.10.016_bib0285","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.urology.2010.11.050","article-title":"Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors","volume":"77","author":"Canter","year":"2011","journal-title":"Urology."},{"key":"10.1016\/j.nefro.2018.10.016_bib0290","first-page":"38","article-title":"Prevalence of anemia and chronic kidney disease in cancer patients: Clinical significance for 1-year mortalit","volume":"53","author":"Nakamura","year":"2011","journal-title":"Nihon Jinzo Gakkai Shi."},{"key":"10.1016\/j.nefro.2018.10.016_bib0295","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.thromres.2014.04.002","article-title":"Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality","volume":"134","author":"K\u00f6nigsbr\u00fcgge","year":"2014","journal-title":"Thromb Res."},{"key":"10.1016\/j.nefro.2018.10.016_bib0300","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ejim.2010.04.011","article-title":"Under-recognized renal insufficiency in hospitalized patients: Implications for care","volume":"21","author":"de Francisco","year":"2010","journal-title":"Eur J Intern Med."},{"key":"10.1016\/j.nefro.2018.10.016_bib0305","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/s12885-016-2532-6","article-title":"Chronic kidney disease and the risk of cancer: An individual patient data meta-analysis of 32,057 participants from 6prospective studies","volume":"16","author":"Wong","year":"2016","journal-title":"BMC Cancer"},{"key":"10.1016\/j.nefro.2018.10.016_bib0310","first-page":"253","article-title":"Chronic kidney disease and cancer: A troubling connection","volume":"23","author":"Stengel","year":"2010","journal-title":"J Nephrol."},{"issue":"Supl.","key":"10.1016\/j.nefro.2018.10.016_bib0315","article-title":"C\u00e1ncer en el trasplantado renal: \u00bfse puede prevenir?","volume":"9","author":"Arias","year":"2018","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.nefro.2018.10.016_bib0320","unstructured":"Cancer report. En: Clayton P, McDonald S, Hurst K, editores. Australia and New Zealand Dialysis and Transplant Registry. 2013 Annual report. 36th ed. Adelaide: ANZDATA; 2014."},{"key":"10.1016\/j.nefro.2018.10.016_bib0325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.juro.2012.03.006","article-title":"Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: A systematic review and meta-analysis","volume":"188","author":"Kim","year":"2012","journal-title":"J Urol."},{"key":"10.1016\/j.nefro.2018.10.016_bib0330","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrneph.2013.273","article-title":"Risk of chronic kidney disease after cancer nephrectomy","volume":"10","author":"Li","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.nefro.2018.10.016_bib0335","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.juro.2009.07.004","article-title":"Guideline for management of the clinical T1 renal mass","volume":"182","author":"Campbell","year":"2009","journal-title":"J Urol."},{"key":"10.1016\/j.nefro.2018.10.016_bib0340","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","article-title":"EAU guidelines on renal cell carcinoma: 2014 update","volume":"67","author":"Ljungberg","year":"2015","journal-title":"Eur Urol."},{"key":"10.1016\/j.nefro.2018.10.016_bib0345","first-page":"823","article-title":"Potential for molecularly targeted therapy against epidermal growth factor receptor ligands","volume":"29","author":"Miyamoto","year":"2009","journal-title":"Anticancer Res."},{"key":"10.1016\/j.nefro.2018.10.016_bib0350","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2174\/156800911795655985","article-title":"VEGF\/VEGFR pathway inhibitors as anti-angiogenic agents: Present and future","volume":"11","author":"Sharma","year":"2011","journal-title":"Curr Cancer Drug Targets."},{"key":"10.1016\/j.nefro.2018.10.016_bib0355","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.nefro.2018.10.016_bib0360","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.nefro.2018.10.016_bib0365","first-page":"4","article-title":"The biology and therapeutic approach to BRAF-Mutant cutaneous melanoma","volume":"13","author":"Wood","year":"2017","journal-title":"AJHO."},{"key":"10.1016\/j.nefro.2018.10.016_bib0370","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.2174\/092986712802002464","article-title":"Role of PARP inhibitors in cancer biology and therapy","volume":"19","author":"Davar","year":"2012","journal-title":"Curr Med Chem."},{"key":"10.1016\/j.nefro.2018.10.016_bib0375","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ctrv.2016.03.002","article-title":"Targeting CDK4\/6 in patients with cancer","volume":"45","author":"Hamilton","year":"2016","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.nefro.2018.10.016_bib0380","doi-asserted-by":"crossref","first-page":"796","DOI":"10.2215\/CJN.12871117","article-title":"Chimeric antigen receptor T cell therapy and the kidney: What the nephrologist needs to know","volume":"13","author":"Jhaveri","year":"2018","journal-title":"Clin J Am Soc Nephrol."},{"key":"10.1016\/j.nefro.2018.10.016_bib0385","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nature Reviews Cancer"},{"key":"10.1016\/j.nefro.2018.10.016_bib0390","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2174\/1574884712666180802095521","article-title":"Antibody-drug conjugates: A review on the epitome of targeted anti-cancer therapy","volume":"13","author":"Hasan","year":"2018","journal-title":"Curr Clin Pharmacol."},{"key":"10.1016\/j.nefro.2018.10.016_bib0395","doi-asserted-by":"crossref","first-page":"74","DOI":"10.5301\/jo-n.5000010","article-title":"Chronic kidney disease as complication of cancer","volume":"1","author":"Selamet","year":"2017","journal-title":"Onco-Nephrol"},{"key":"10.1016\/j.nefro.2018.10.016_bib0400","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: Past, present and future","volume":"29","author":"Pezarella","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.nefro.2018.10.016_bib0405","doi-asserted-by":"crossref","unstructured":"Cosmai L, Porta C, Perazella MA, Launay-Vacher V, Rosner MH, Jhaveri KD, et al. Opening an onconephrology clinic: Recommendations and basic requirements. Nephrol Dial Transplant. 2018;33(9):1503-1510.","DOI":"10.1093\/ndt\/gfy188"},{"key":"10.1016\/j.nefro.2018.10.016_bib0410","doi-asserted-by":"crossref","first-page":"e1445952","DOI":"10.1080\/2162402X.2018.1445952","article-title":"Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy","volume":"26","author":"Xipell","year":"2018","journal-title":"Oncoimmunology."}],"container-title":["Nefrolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021169951930027X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S021169951930027X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:53:53Z","timestamp":1759323233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S021169951930027X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S021169951930027X"],"URL":"https:\/\/doi.org\/10.1016\/j.nefro.2018.10.016","relation":{},"ISSN":["0211-6995"],"issn-type":[{"value":"0211-6995","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Onco-Nefrolog\u00eda: c\u00e1ncer, quimioterapia y ri\u00f1\u00f3n","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2018.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Sociedad Espa\u00f1ola de Nefrolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}